Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Status:
RECRUITING
Trial end date:
2029-01-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.